COMPANY PROFILE

Motricity

Explore full profile

Bellevue, United StatesFounded 2001Telecom

Valuation $500M–1B Latest valuation · 2007

Revenue $10–50M Latest reported FY

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

At a glance

Status: Low Activity
Founded: 2001
Headquarters: Bellevue, United States
Employees: 165
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Telecom
Sector: Telecom, Rumoured $1B
Business model: SaaS
Client focus: b2b
Links: LinkedIn

Latest news

Press, funding announcements and product moves mentioning Motricity.

See all news

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Dec 2007	$185M	$740M	Carl Icahn · NEA	—
LATE VCOther financing	Feb 2007	$50M	$200M	Carl Icahn	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Motricity website traffic

Latest recorded traffic for Motricity is 1.2K monthly website visits, up 26.3% over the last three months. Motricity's team declined 9.3% over the past year.

Latest monthly visits1.2K 3-month web change+26.3% 1-year team growth-9.3%

Monthly website visitsAug 2020–Jun 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTcAMPfield TherapeuticsOral biopharmaceutical therapies for inflammatory bowel disease and other immune-mediated inflammatory diseases	San Diego, United States	Operational	19	$180M	$720M
BMBeeline MedicinesPrecision therapies for autoimmune and inflammatory diseases.	Stamford, United States	Operational
ATAirNexis TherapeuticsPulmonary disease therapeutics for chronic obstructive pulmonary disease	Palo Alto, United States	Operational
ATAlveus TherapeuticsNext-generation obesity and metabolic disease therapies	Philadelphia, United States	Operational
BBBraveheart BioLate-stage therapeutics for hypertrophic cardiomyopathy	San Francisco, United States	Operational
EXExcellergyTrifunctional inhibitors for severe allergic disease control	Palo Alto, United States	Acquired
CTCrystalys TherapeuticsClinical-stage biopharmaceutical developing therapies for gout	San Diego, United States	Operational
ATAntares TherapeuticsDevelopment of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments	Boston, United States	Operational